OakChart

Latigo Biotherapeutics Inc

LTGOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.52+0.19 (1.43%)
2026-11-12 00:07 CET
Market cap
883.77 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-20.95 USD m
Free cash flow, TTM
-19.56 USD m
EPS diluted, TTM
-0.32
P/E
-
Compare

Price

LTGO against its 20 and 50-day averages
2050beat
10.0015.0020.0025.001.7M3.3MVolumeAug 26Sep 26Oct 26Nov 26LTGOclose 13.5220-day 14.5050-day 17.3913.5252w high52w low

47.9% under the 52-week high of 25.93 on 27 Aug 2026. 52-week low 10.24 on 5 Nov 2026. Last 15 sessions, 72.6% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Profile

LTGO
52-week range, 21% of the way up
10.2425.93

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.

IPOAug 07, 2026
ATR, 14d1.63
Rel volume0.67
Short float3.19%
Insider own55.55%
Inst own16.59%

Snapshot

6 groups

Valuation

Index-
Market Cap896.37M
Enterprise Value496.15M
Income-
Sales-
Book/sh5.94
Cash/sh6.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOAug 07, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.28
P/C2.23
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio29.11
Current Ratio29.11
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.53
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q22.64%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.12.08% -

Ownership

Insider Own55.55%
Insider Trans0.77%
Inst Own16.59%
Inst Trans17.40%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-6.75%
SMA50-22.23%
SMA200-26.44%
Trades-

Technical

Shs Outstand66.30M
Shs Float29.47M
Short Float3.19%
Short Ratio3.19
Short Interest0.94M
52W High25.93 -47.86%
52W Low10.24 32.03%
Volatility17.77% 11.64%
ATR (14)1.63
RSI (14)41.09
Beta-
Rel Volume0.67
Avg Volume295.08K
Volume198,829

Performance

Perf Week-3.70%
Perf Month-13.94%
Perf Quarter-32.60%
Perf Half Y-
Perf YTD-35.62%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price52.25
Prev Close13.33
Price13.52
Change %1.43%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedLLeerink PartnersOutperform$36+166.3%
Sep 01, 2026InitiatedJJefferiesBuy$50+269.8%
Sep 01, 2026InitiatedGGuggenheimBuy$50+269.8%
Sep 01, 2026InitiatedGGoldmanBuy$73+439.9%

Peers

Mkt cap
TickerCompanyMkt cap
VRTXVertex Pharmaceuticals Inc138.69B
XENEXenon Pharmaceuticals Inc4.14B
LXRXLexicon Pharmaceuticals Inc832.59M
TRVITrevi Therapeutics Inc2.11B
PRAXPraxis Precision Medicines Inc9.68B
AXSMAxsome Therapeutics Inc7.85B
PCRXPacira BioSciences Inc1.46B
HRTXHeron Therapeutics Inc68.36M
SUPNSupernus Inc6.12B
NBIXNeurocrine Biosciences Inc17.65B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Foresite Capital Management V,10% OwnerAug 10 '26Buy18.00140,0002,520,0002,008,024Aug 10 08:21 PM
Tananbaum James B.DirectorAug 10 '26Buy18.00140,0002,520,0002,008,024Aug 10 08:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.550-0.626-0.5500.000.004
2026Q22026-09-03-0.617-0.617-0.3890.000.003
2026Q12026-06-03-2.225--0.3630.00--
2026Q4---0.526--0.004
2027Q1---0.510--0.002
2027Q2---0.500--0.002
2027Q3---0.525--0.002
2027Q4---0.590--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-053000.000.000.00
2026Q4S2026-09-043000.000.000.00
2026Q4S2026-08-313000.000.000.00
2026Q4R2026-11-05210-0.56-0.75-0.37
2026Q4R2026-09-04200-0.71-0.75-0.66
2026Q4R2026-08-31200-0.71-0.75-0.66
2026Q4E2026-11-05430-0.53-0.75-0.36
2026Q4E2026-11-04400-0.78-0.86-0.66
2026Q4E2026-10-09400-0.78-0.86-0.66
2026Q4E2026-09-04400-0.78-0.86-0.66
2026Q4E2026-08-31400-0.78-0.86-0.66
2026Q3S2026-09-043000.000.000.00
2026Q3S2026-09-023000.000.000.00
2026Q3S2026-08-313000.000.000.00

Estimate history

EPS, annual-0.968-1.726
Period20242025
EPS, quarterly-0.331-0.409-0.374-0.363-0.389-0.316
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual00
Period20242025
Sales, quarterly000000
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual63.23863.23866.299
Period20242025MRQ
Shares, quarterly63.23863.23866.29963.23866.29966.299
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.050.250.24
Gross Profit-0.05-0.25-0.24
Selling, General and Administrative Excl. Other22.88110.1463.21
Research and Development17.5099.5356.78
Other Operating Expense0.000.000.00
Operating Income-22.93-110.39-63.45
Interest Expense0.700.000.00
Unusual Expense-0.571.670.00
Net Income Before Taxes-20.95-109.17-61.18
Income Taxes0.000.000.00
Consolidated Net Income-20.95-109.17-61.18
Net Income From Continuing Operations-20.95-109.17-61.18
Net Income-20.95-109.17-61.18
EPS (Recurring)-0.32-1.71-0.97
EPS (Basic, Before Extraordinaries)-0.32-1.73-0.97
EPS (Diluted)-0.32-1.73-0.97
EBITDA-22.88-110.14-63.21
Non-Operating Income (Expense)2.112.902.27
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense2.546.722.77
Shares Outstanding66.3063.2463.24
Market Capitalization883.77883.77-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.050.050.050.070.070.07
Gross Profit-0.05-0.05-0.05-0.07-0.07-0.07
Selling, General and Administrative Excl. Other22.8825.7623.3924.6625.6821.45
Research and Development17.5021.2317.6322.1022.9218.69
Other Operating Expense0.000.000.000.000.000.00
Operating Income-22.93-25.81-23.44-24.72-25.75-21.51
Interest Expense0.700.250.000.000.000.00
Unusual Expense-0.570.000.000.800.93-0.05
Net Income Before Taxes-20.95-25.80-22.96-24.80-25.84-20.95
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-20.95-25.80-22.96-24.80-25.84-20.95
Net Income From Continuing Operations-20.95-25.80-22.96-24.80-25.84-20.95
Net Income-20.95-25.80-22.96-24.80-25.84-20.95
EPS (Recurring)-0.32-0.39-0.36-0.37-0.40-0.33
EPS (Basic, Before Extraordinaries)-0.32-0.39-0.36-0.37-0.41-0.33
EPS (Diluted)-0.32-0.39-0.36-0.37-0.41-0.33
EBITDA-22.88-25.76-23.39-24.66-25.68-21.45
Non-Operating Income (Expense)2.110.260.470.720.840.51
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense2.542.141.981.821.681.48
Shares Outstanding66.3066.3063.2466.3063.2463.24
Market Capitalization883.771,200.02----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments69.6317.92
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets4.203.25
Total Current Assets73.8321.16
Net Property, Plant & Equipment1.071.41
Total Investments and Advances0.000.00
Other Assets0.620.29
Total Assets75.5222.86
Short Term Debt Incl. Current Port. of LT Debt0.560.39
Accounts Payable5.017.07
Other Current Liabilities12.876.98
Total Current Liabilities18.4514.44
Long Term Debt0.130.46
Provision for Risks Charges0.000.00
Other Liabilities0.040.04
Total Liabilities18.6114.93
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value288.58137.53
Common Equity-231.67-129.60
Total Shareholders Equity56.917.93
Accumulated Minority Interest0.000.00
Total Equity56.917.93
Total Liabilities & Stockholders Equity75.5222.86
Book Value Per Share-3.66-2.05
Tangible Book Value Per Share-3.66-2.05
Price to Book Ratio2.24-
Return on Assets-221.93-
Return on Equity-336.74-
Return on Invested Capital-191.40-728.89
Quick Ratio4.001.47
Current Ratio4.001.47

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-20.95-109.17-61.18
Depreciation0.050.250.24
Other Funds (Non Cash)2.838.843.10
Funds from Operations-18.07-100.08-57.84
Extraordinary Item0.000.000.00
Changes in Working Capital-1.462.526.89
Cash from Operating Activities-19.52-97.56-50.95
Capital Expenditures-0.04-0.14-0.07
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments0.000.000.00
Purchase of Investments0.000.000.00
Sale Or Maturity of Investments0.000.000.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities-0.04-0.14-0.07
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock365.93149.500.61
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock365.93149.500.61
Proceedsfrom Stock Options365.43149.500.61
Issuance or Reduction of Debt, Net-0.170.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities365.76149.500.61
Net Change in Cash346.2051.80-50.42
Free Cash Flow-19.56-97.69-51.03
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments401.4155.2042.37---
Short Term Receivables0.000.000.00---
Inventories0.000.000.00---
Other Current Assets5.034.004.47---
Total Current Assets406.4459.2046.84---
Net Property, Plant & Equipment1.581.760.90---
Total Investments and Advances0.000.000.00---
Other Assets0.433.802.84---
Total Assets408.4664.7650.58---
Short Term Debt Incl. Current Port. of LT Debt0.7030.600.50---
Accounts Payable5.083.574.46---
Other Current Liabilities8.1717.419.53---
Total Current Liabilities13.9651.5814.49---
Long Term Debt0.480.650.05---
Provision for Risks Charges0.000.000.00---
Other Liabilities0.040.040.04---
Total Liabilities14.4852.2614.58---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.00288.58288.58---
Common Equity393.97-276.08-252.58---
Total Shareholders Equity393.9712.5036.00---
Accumulated Minority Interest0.000.000.00---
Total Equity393.9712.5036.00---
Total Liabilities & Stockholders Equity408.4664.7650.58---
Book Value Per Share5.94-4.16-3.99---
Tangible Book Value Per Share5.94-4.16-3.99---
Full-Time Employees-6659---
Price to Book Ratio2.24-4.35----
Return on Invested Capital-5.31-196.17-63.68---
Quick Ratio29.111.153.23---
Current Ratio29.111.153.23---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-20.95-25.80-22.96-24.80-25.84-20.95
Depreciation0.050.050.050.070.070.07
Other Funds (Non Cash)2.832.582.102.762.701.51
Funds from Operations-18.07-23.17-20.81-21.97-23.07-19.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.461.89-6.262.051.51-1.78
Cash from Operating Activities-19.52-21.28-27.07-19.91-21.56-21.16
Capital Expenditures-0.04-0.110.000.00-0.03-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.04-0.110.000.00-0.03-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock365.93-0.82-0.2350.05-0.0099.43
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock365.93-0.82-0.2350.05-0.0099.43
Proceedsfrom Stock Options365.43-0.82-0.2349.95-0.0099.43
Issuance or Reduction of Debt, Net-0.1735.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities365.7634.18-0.2350.05-0.0099.43
Net Change in Cash346.2012.79-27.3030.14-21.5978.17
Free Cash Flow-19.56-21.39-27.07-19.91-21.59-21.26

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.19%0.9M29.5M338.40K
2026-10-152.67%0.8M29.5M374.52K
2026-09-303.01%0.8M27.7M391.26K
2026-09-151.62%0.4M27.7M337.04K
2026-08-311.11%0.3M27.7M407.72K
2026-08-140.51%0.1M26.4M820.93K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-03SEC
2026-10-29SCHEDULE 13GSEC
2026-09-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-08-18SCHEDULE 13GSEC
2026-08-17SCHEDULE 13GSEC
2026-08-17SCHEDULE 13DSEC
2026-08-13SCHEDULE 13GSEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-07424B4SEC
2026-08-06EFFECTEffectiveness filing by commission orderSEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-06CERTSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-085.04M200
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC4.34%
Aberdeen Group plc1.41%
Sanofi1.01%
UBS Group AG0.44%
GEODE CAPITAL MANAGEMENT, LLC0.33%
Squarepoint Ops LLC0.05%
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.0.04%
Cambridge Investment Research Advisors, Inc.0.02%
CITIGROUP INC0.00%
Nuveen, LLC0.00%

Funds

Fund% owned
VANGUARD RUSSELL 2000 INDEX FUND0.01%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND0.00%
VANGUARD RUSSELL 3000 INDEX FUND0.00%

OakChart. LTGO. Cached 15 minutes.

Some panels did not load: news.